GlassScriptPhysician profile
Clement A Elechi
NPI 1538146915
$2,388.15
in general payments reported to CMS, 2019-2025
29 companies · $490 in 2025
The $490 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $74.21 · 2021: $131 · 2022: $382 · 2023: $489 · 2024: $298 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,106 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.69 |
| Education | $172.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $751.78 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $195.99 | 2019-2025 | |
| Emd Serono, INC. | $164.94 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $158.16 | 2019-2025 | Austedo Xr, Austedo Xr |
| Ucb, INC. | $121.28 | 2021-2025 | Rystiggo, Briviact |
| Alexion Pharmaceuticals, INC. | $118.84 | 2023-2025 | Ultomiris |
| Biogen, INC. | $99.78 | 2023-2025 | Tysabri, Spinraza |
| Genentech USA, INC. | $90.42 | 2019-2025 | Ocrevus Zunovo |
| Pfizer INC. | $83.67 | 2019-2025 | |
| Ge Healthcare | $63.16 | 2019-2021 | |
| Tactile Systems Technology INC | $56.17 | 2022 | |
| Hospira, INC. | $53.95 | 2022-2023 | |
| Lilly USA, LLC | $40.92 | 2022-2024 | Emgality |
| Sunovion Pharmaceuticals INC. | $39.00 | 2019 | |
| Axsome Therapeutics, INC. | $33.86 | 2025 | Sunosi |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $33.79 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $31.72 | 2025 | Purified Cortrophin Gel |
| Argenx US, INC. | $29.90 | 2024 | Vyvgart Hytrulo |
| E.R. Squibb & Sons, L.L.C. | $29.76 | 2020 | |
| Jazz Pharmaceuticals INC. | $26.98 | 2025 | |
| Horizon Therapeutics Plc | $22.45 | 2022 | |
| Neurocrine Biosciences, INC. | $22.30 | 2025 | |
| Neurelis, INC. | $19.87 | 2022 | |
| Impel Pharmaceuticals INC. | $18.84 | 2023 | Trudhesa |
| Inspire Medical Systems, INC. | $18.28 | 2023 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $18.23 | 2022 | |
| Resmed Corp | $18.09 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $14.76 | 2019 | |
| Boston Scientific Corporation | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clement Elechi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.